CASI Pharmaceuticals, Inc. (CASIF): Shareholders' Equity
-$37.28M
As of 2025-12-31
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$37.28M | n/m | 2026-05-15, Balance as of period end |
| 2024-12-31 | $1.85M | -92.3% | 2026-05-15, Balance as of period end |
| 2023-12-31 | $24.16M | -45.8% | 2026-05-15, Balance as of period end |
| 2022-12-31 | $44.57M | -47.3% | 2025-03-31, Balance as of period end |
| 2021-12-31 | $84.50M | +3.6% | 2024-03-28, Balance as of period end |
| 2020-12-31 | $81.54M | n/a | 2023-04-26, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | -$37.28M | n/m |
| Scynexis Inc (SCYX) | 2025-12-31 | $49.38M | -10.4% |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | -$74.34M | n/m |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $22.81M | -20.9% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $683.43M | -9.8% |
| Alumis Inc. (ALMS) | 2025-12-31 | $301.30M | +15.8% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $306.13M | -28.6% |
| Celularity Inc (CELU) | 2025-12-31 | -$38.06M | n/m |
| uniQure N.V. (QURE) | 2025-12-31 | $198.90M | n/m |
Compare CASIF, SCYX, EVFM, SLGL side by side · Screen every company in Pharmaceutical Preparations ↗